Bioventus (BVS) vs Delcath Systems (DCTH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Delcath Systems (DCTH) has outperformed Bioventus (BVS) over the past year, gaining 109.7% versus a gain of 36.5%. Over five years, DCTH leads with a +92.9% price change compared with -21.0% for BVS. Bioventus is the larger company by market cap ($676.5 million vs $653.7 million), about 1.0 times the size, while Delcath Systems is growing revenue faster (+129.1% vs -0.9%).
On valuation, Bioventus trades at a lower forward P/E (11.1x vs 69.0x for Delcath Systems). Bioventus converts more of its revenue into profit, with a net margin of 4.0% versus 3.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BVS | DCTH |
|---|---|---|
| Share price | $9.88 | $18.79 |
| Market cap | $676.53M | $653.67M |
| 1-day change | -0.70% | -2.34% |
| YTD return | +32.80% | +86.04% |
| 1-year return | +36.46% | +109.71% |
| 5-year return | -21.02% | +92.92% |
| P/E ratio (TTM) | 12.20 | 117.44 |
| Forward P/E | 11.13 | 68.95 |
| EPS (TTM) | $0.81 | $0.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $568.09M | $85.23M |
| Revenue growth (YoY) | -0.91% | +129.08% |
| Net income (latest FY) | $22.73M | $2.70M |
| Gross margin | 68.33% | 86.16% |
| Operating margin | 9.50% | 0.77% |
| Net margin | 4.00% | 3.17% |
| 52-week high | $15.89 | $22.51 |
| 52-week low | $7.02 | $8.49 |
| Distance from 52-week high | -37.83% | -16.53% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +68.02% | +52.21% |
| Average volume | 536.81K | 497.48K |
| Shares outstanding | 68.47M | 34.79M |
| Employees | 960 | 156 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DCTH has outperformed BVS by 73.2 percentage points over the past year.
- Delcath Systems trades at a higher earnings multiple (117.4x vs 12.2x trailing P/E).
- Delcath Systems grew revenue faster in its latest fiscal year (+129.08% vs -0.91%).
About Bioventus
BVS stock →Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle.
Health Care · Medical/Dental Instruments · 960 employees
About Delcath Systems
DCTH stock →Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Health Care · Medical/Dental Instruments · 156 employees
BVS vs DCTH FAQ
Which is bigger, Bioventus or Delcath Systems?
Bioventus (BVS) is larger, with a market capitalization of $676.53M compared with $653.67M for Delcath Systems (DCTH).
Which stock has performed better over the past year, BVS or DCTH?
DCTH returned +109.71% over the past 12 months, compared with +36.46% for BVS (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BVS or DCTH?
BVS has the lower trailing P/E at 12.2, versus 117.4 for DCTH. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Bioventus and Delcath Systems in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.